Literature DB >> 12595535

Conformation-dependent post-translational glycosylation of tyrosinase. Requirement of a specific interaction involving the CuB metal binding site.

Concepcion Olivares1, Francisco Solano, Jose C García-Borrón.   

Abstract

Tyrosinase, the rate-limiting enzyme in mammalian melanogenesis, is a copper-containing transmembrane glycoprotein. Tyrosinase undergoes a complex post-translational processing before reaching the melanosomal membrane. This processing involves N-glycosylation in several sites, including one located in the CuB copper binding site, movement from the endoplasmic reticulum (ER) to the Golgi, copper binding, and sorting to the melanosome. Aberrant processing is causally related to the depigmented phenotype of human melanomas. Moreover, some forms of albinism and several other pigmentary syndromes are considered ER retention diseases or trafficking defects. A critical step in tyrosinase maturation is the acquisition of an ER export-competent conformation recognized positively by the ER quality control system. However, the minimal structural requirements allowing exit from the ER to the Golgi have not yet been identified for tyrosinase or other melanosomal proteins. We addressed this question by analyzing the enzymatic activity and glycosylation pattern of mouse tyrosinase point mutants and chimeric constructs, where selected portions of tyrosinase were replaced by the homologous fragments of the highly similar tyrosinase-related protein 1. We show that a completely inactive tyrosinase point mutant lacking a critical histidine residue involved in copper binding is nevertheless able to exit from the ER and undergo further processing. Moreover, we demonstrate that tyrosinase displays at least two sites whose glycosylation is post-translational and most likely conformation-dependent and that a highly specific interaction involving the CuB site is essential not only for correct glycosylation but also for exit from the ER and enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595535     DOI: 10.1074/jbc.M300658200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking.

Authors:  Mary S Matsui; Michael J Petris; Yoko Niki; Nevena Karaman-Jurukovska; Neelam Muizzuddin; Masamitsu Ichihashi; Daniel B Yarosh
Journal:  J Invest Dermatol       Date:  2014-10-22       Impact factor: 8.551

2.  C-terminus glycans with critical functional role in the maturation of secretory glycoproteins.

Authors:  Daniela Cioaca; Simona Ghenea; Laurentiu N Spiridon; Marioara Marin; Andrei-Jose Petrescu; Stefana M Petrescu
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

3.  Differentiation of adipose-derived stem cells to functional CD105neg CD73low melanocyte precursors guided by defined culture condition.

Authors:  Gabriela Zavala; Carolina Sandoval; Daniel Meza; Rafael Contreras; Walter Gubelin; Maroun Khoury
Journal:  Stem Cell Res Ther       Date:  2019-08-09       Impact factor: 6.832

4.  Enhancing Catecholase Activity of a Recombinant Human Tyrosinase Through Multiple Strategies.

Authors:  Arman Shahrisa; Maryam Nikkhah; Hadi Shirzad; Roudabeh Behzadi; Majid Sadeghizadeh
Journal:  Iran J Biotechnol       Date:  2020-04-01       Impact factor: 1.671

5.  The consequences of deglycosylation of recombinant intra-melanosomal domain of human tyrosinase.

Authors:  Monika B Dolinska; Yuri V Sergeev
Journal:  Biol Chem       Date:  2017-12-20       Impact factor: 4.700

Review 6.  On the Metal Cofactor in the Tyrosinase Family.

Authors:  Francisco Solano
Journal:  Int J Mol Sci       Date:  2018-02-23       Impact factor: 5.923

7.  Conjugation with Dihydrolipoic Acid Imparts Caffeic Acid Ester Potent Inhibitory Effect on Dopa Oxidase Activity of Human Tyrosinase.

Authors:  Raffaella Micillo; Julia Sirés-Campos; José Carlos García-Borrón; Lucia Panzella; Alessandra Napolitano; Conchi Olivares
Journal:  Int J Mol Sci       Date:  2018-07-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.